In 1986, Gordon Guyatt and David Sackett published a methodology in the New England Journal of Medicine for running randomized controlled trials on a single patient. Not a cohort. Not a population. One person, randomized treatment periods, blinded where possible, repeated crossovers until the answer was clear or the question was settled.
That was nearly forty years ago. The method has its own CONSORT reporting standards. Twenty-five checklist items and forty-four sub-items governing how to design, execute, and report a rigorous experiment on yourself. Prospective protocols. Randomization schedules. Washout periods. Prespecified outcomes. Carryover modeling. The full apparatus of experimental science, scaled to one.
The objection to this kind of work has never been epistemological. It has been institutional.
The Experiment That Tells You You’re Wrong
In the I-STOP-AFib study, 446 people with paroxysmal atrial fibrillation enrolled to test their own suspected triggers. They alternated randomized exposure and avoidance periods while outcomes were captured through mobile tools and an ECG device.
Caffeine was the most commonly suspected trigger. The participants were sure.
The study found no evidence that caffeine caused atrial fibrillation. None. Alcohol showed a consistent signal. Caffeine did not.
320 people completed the study. The experiment did not meet its primary endpoint for quality of life improvement. But participants who went through the trigger testing subsequently reported fewer AF episodes than controls. Something about subjecting your beliefs to a structured test changed the relationship between the patient and the condition.
This is the dividing line. Self-experimentation becomes science when the experiment has the structural capacity to tell you that your favorite theory is wrong. Not when it confirms what you already believe. When it can falsify it. A food diary is not science. A randomized crossover with blinding and prespecified outcomes is.
The Patient They Could Not Convince
The SAMSON trial took sixty people who had quit statins because of side effects. It randomized them across twelve one-month periods: four on atorvastatin, four on placebo, four on nothing. Daily symptom reporting through an app. No clinician arguing. No lecture about compliance. Just the data.
Mean symptom intensity was 16.3 during statin months and 15.4 during placebo months. Statistically indistinguishable. The symptoms were real. They were also present when the participants took nothing but a sugar pill. This is the nocebo effect: the inverse of placebo, where the expectation of harm produces symptoms that have no pharmacological cause. The nocebo ratio was 0.90.
Six months later, half of them were back on statins.
No population study could have produced that result for those specific people. A doctor saying “the evidence suggests your side effects are nocebo” is a claim of authority. The patient running a blinded crossover on their own body and watching the data accumulate across twelve months is evidence. Different epistemic object entirely.
StatinWISE scaled the idea to 200 randomized, double-blind N-of-1 trials across UK primary care. Same result. Statin-placebo symptom difference of negative 0.11 on a ten-point scale. Not clinically detectable.
Two hundred individual experiments. Two hundred sets of evidence produced by the people who needed it most, about the question only they could answer.
What AI Actually Changes
The barrier to N-of-1 was never statistics. It was operations. Someone had to randomize treatment periods, remind the patient, collect diaries, enter data, plot results, and run serial analyses accounting for carryover, autocorrelation, and time trends. For one person. The economics never worked inside an institution built around populations.
Continuous glucose monitors are now over the counter. Wearable ECG monitors transmit from your wrist. Blood pressure, sleep architecture, heart rate variability, activity, and mood are captured continuously by devices people already own. The measurement substrate for dense repeated-observation experiments is sitting in people’s pockets.
AI closes the operational gap. Protocol drafting. Literature review for intervention candidates. Scheduling and randomization. Adherence prompts. Data cleaning. Model fitting. Visualization. Plain-language interpretation of serial measurements with explicit uncertainty.
But AI does something else that changes the scale of the entire proposition. It can find experiments that are already running.
Someone wearing an Apple Watch and logging meals in MyFitnessPal and tracking supplements is producing a dense longitudinal dataset of exposures, biomarkers, and outcomes. They are running an N-of-1 experiment on themselves. They just do not know it. AI can identify a cohort of people sharing a particular biomarker who eat differently. Find the subset who also track a specific supplement. Now you have natural comparison groups that nobody designed. Possible experiments can be computationally discovered from passive behavioral data, and targeted invitations can recruit people into more structured versions of experiments they were already running.
None of that creates causality by itself. An LLM that mines personal data until something looks significant recreates the exact researcher-degrees-of-freedom problem that discredited parts of institutional science, only faster. The scientifically valuable architecture is discovery from passive data followed by prospective randomized N-of-1 testing. Prediction from correlations is not evidence. A prespecified, randomized, repeated crossover is.
The important distinction: AI lowers the coordination and analysis barrier. It does not lower the scientific standard. It makes the standard accessible and it makes the discovery of what to test scalable.
What Happens When You Aggregate
A single N-of-1 experiment tells you what works for you. A thousand N-of-1 experiments on the same question, combined through hierarchical models that preserve individual effects while estimating population distributions, produce something qualitatively different. Evidence that is both individually relevant and population-scale powerful. Built from the bottom up. No institutional trial required.
This is not a theoretical possibility. The statistical methodology for combining series of N-of-1 trials into population-level inference already exists. Bayesian hierarchical models can partially pool individual estimates so people with sparse or noisy data borrow strength from the group without forcing everyone to have the same treatment effect. The design starts from repeated individual contrasts rather than estimating one population mean and attempting underpowered subgroup rescue afterward.
Now apply the passive data layer. Millions of people are already generating the raw material. AI discovers candidate experiments from that data. Intelligent sample selection builds optimal pools. Randomized selection within those pools creates rigorous comparison. The aggregation layer cleans, combines, and surfaces findings.
None of this has been demonstrated at scale. The statistical methodology is proven. The consumer infrastructure is deployed. The AI orchestration layer is forming. Whether the combination produces reliable population-level evidence or collapses under noise, dropout, and data quality problems is an empirical question the next five years will answer. But the components exist and the trajectory is visible.
Communities With a Protocol
Two hundred million people ask ChatGPT health questions every week. Forty million do so every day. Seven in ten of those conversations happen outside clinic hours, when no doctor is available and no institution is open. The behavioral shift has already happened. What has not happened is any mechanism for verifying whether the answers are worth following.
A review in Nature Digital Medicine found that 88% of studies evaluating LLMs for medical purposes reported incorrect or incomplete output. People are asking. The answers are unreliable. And nobody is giving them a way to check.
N-of-1 is the verification layer. And when people with the same condition discover they can verify together, communities form. This is not speculative. It has already happened.
The OpenAPS community built an open-source automated insulin delivery system because the commercial product did not exist yet. Patients with Type 1 diabetes designed the software, distributed it, iterated on it, and accumulated millions of real-world operating hours. A randomized trial in the New England Journal of Medicine later confirmed what the community already knew from their own data. The patients did not wait for the product roadmap. They built the product, used it, and the institutional validation came after.
Now imagine the next version. Someone with chronic migraines wears a smartwatch, logs meals and supplements in an app, and has already asked an LLM which magnesium and riboflavin protocols have evidence behind them. She is generating experimental data. She just does not have a protocol. AI identifies 340 other people in the same data landscape with similar biomarker patterns and migraine frequency. It proposes a structured N-of-1 trial design. Some of those people join voluntarily. Others are already running something close enough that their existing data qualifies with minimal additional structure. The community provides the protocol, the measurement framework, and the aggregation. Each participant gets her own answer. The combined data produces population-level evidence. Nobody asked an institution for permission.
The intervention spectrum runs from fully legal and low-risk (supplement combinations, dietary protocols, exercise regimens) through the gray market (research peptides, nootropics, compounds available under “research use only” labeling that everyone knows are being used for something other than research). AI is the organizing layer at every stage. Identifying candidate interventions. Designing trial protocols. Matching participants. Discovering natural experiments in existing data streams. Cleaning and aggregating results. Surfacing findings back to the community.
None of this eliminates the problems institutions were built to solve. Quality control, safety surveillance, adverse event detection across large populations, liability when interventions cause harm. Communities that organize around gray-market interventions inherit those problems whether they acknowledge them or not. The question is not whether the problems disappear. They do not. The question is whether the institutional monopoly on solving them holds. Independent assays, cryptographic provenance, distributed safety reporting, and reputation systems are all technically feasible. Whether communities will actually build and sustain them is the harder test.
This is not a fantasy about decentralized drug development. It is the observable trajectory of tools that already exist, behaviors that are already happening, and organizational patterns that AI makes trivially composable. The trajectory does not require the problems to be solved. It requires enough people to decide the problems are worth solving outside the institutions that currently own them.
The Monopoly That Never Was
N-of-1 trials do not replace population studies. They cannot detect rare events across thousands of people. They cannot establish long-term safety. They work for a specific class of problems: reversible interventions, frequently measurable outcomes, genuine therapeutic uncertainty, and conditions stable enough for repeated comparison. That boundary is real and permanent.
But within that boundary, the methodology generates causal evidence directly relevant to individual treatment decisions. The aggregation layer scales that evidence to populations without sacrificing individual relevance. The community layer organizes participants around shared conditions. The passive data layer discovers experiments nobody planned and nobody funded.
The methodology is forty years old. The reporting standards are a decade old. The measurement infrastructure is consumer electronics. The analysis and discovery capability is an API call. The community formation is a matching algorithm.
The monopoly on health evidence was never about the science. It was about the infrastructure required to do the science. That infrastructure is dissolving. The science has been in the New England Journal of Medicine since 1986.